Kiniksa Pharmaceuticals, Ltd. (KNSA) closed the last trading session at $24.47, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34.83 indicates a 42.3% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $3.92. While the lowest estimate of $30 indicates a 22.6% increase from the current price level, the most optimist ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive. Inv ...

Core Viewpoint - Kiniksa Pharmaceuticals will participate in the 2024 Wells Fargo Healthcare Conference, indicating ongoing engagement with investors and the healthcare community [1]. Company Overview - Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing therapeutic medicines for patients with significant unmet medical needs [3]. - The company’s immune-modulating assets include ARCALYST®, abiprubart, and mavrilimumab, which target underserved cardiovascular and autoimmune conditions [3]. - Kiniksa aims to differentiate its products based on strong biological rationale and validated mechanisms [3]. Event Details - The fireside chat is scheduled for September 4, 2024, at 8:00 a.m. Eastern Time, showcasing the company's commitment to transparency and investor relations [1]. - A live webcast of the presentation will be available on Kiniksa's website, with a replay accessible within approximately 48 hours post-event [2].

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Whi ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. Our "Recent Price Strength" screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent up ...

The Company evenly splits profits on sales of ARCALYST with Regeneron, where profits are determined after deducting from net sales of ARCALYST certain costs related to the manufacturing and commercialization of ARCALYST. Such costs include but are not limited to (i) the Company's cost of goods sold for product used, sold or otherwise distributed for patient use by the Company; (ii) customary commercialization expenses, including the cost of the Company's field force, and (iii) the Company's cost to market, ...

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Kiniksa Pharmaceuticals shares have added about 22% since the beginning of the year versus the S&P 500's gain of 16.7%. There are no easy answers to this key question, but on ...

2023 | --- | --- | --- | --- | |-------|-------|----------------------------|-------| | | | | | | | | Second Quarter 2024 | | | | | Financial Results and | | | | | Recent Portfolio Execution | | JULY 23, 2024 | --- | --- | --- | --- | |-------|-------|----------------------------|-------| | | | | | | | | Second Quarter 2024 | | | | | Financial Results and | | | | | Recent Portfolio Execution | | Agenda | --- | --- | |---------------------------------------------------------------------------------|-------| ...

ARCALYST (IL-1α and IL-1β cytokine trap) 1 Abiprubart (anti-CD40 monoclonal antibody inhibitor of CD40-CD154 interaction) Financial Results Financial Guidance 2 · Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, July 23, 2024, to discuss second quarter 2024 financial results and recent portfolio execution. · Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email ...

Portfolio Execution ARCALYST (IL-1α and IL-1β cytokine trap) LONDON, July 23, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immunemodulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported second quarter 2024 financial results and recent portfolio execution. ARCALYST net product revenue was $103.4 million for the second quarter of 2024. Since launch in ...